Pricing Log in Create free account

Hemab Therapeutics Holdings, Inc. (COAG) vs Septerna, Inc. (SEPN)

Hemab Therapeutics Holdings, Inc. and Septerna, Inc. are both Biotechnology companies. Hemab Therapeutics Holdings, Inc. and Septerna, Inc. are of similar size ($2.2B and $2.1B). Hemab Therapeutics Holdings, Inc. has the higher net margin (0.00% vs −24.5%) and the higher return on invested capital (0.00% vs −189.0%). Across the 10 metrics below, Hemab Therapeutics Holdings, Inc. leads on 6 and Septerna, Inc. on 4.

Valuation

Metric COAG SEPN Biotechnology median
P/E n/m n/m 10.26
P/S n/m 21.84 9.18
P/B 3.03 5.58 2.05
Price to free cash flow n/m 18.36 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales n/m 18.07 8.98
Earnings yield (117.82%) (1.13%) (34.89%)
Free cash flow yield (5.28%) 5.45% (24.52%)

Profitability

Metric COAG SEPN Biotechnology median
Gross margin — 100.00% 65.16%
Operating margin 0.00% (44.04%) 0.00%
Net margin 0.00% (24.51%) 0.00%
Free cash flow margin 0.00% 118.93% 0.00%
Return on equity 0.00% (6.34%) (50.12%)
Return on assets (31.79%) (4.94%) (45.60%)
Return on invested capital 0.00% (189.01%) 0.00%

Growth

Metric COAG SEPN Biotechnology median
Revenue growth (TTM) — 13,520.11% 6.26%
EPS growth (last fiscal year) — 84.85% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric COAG SEPN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 35.85 4.99 4.89
Net debt to EBITDA — 5.86 1.01

Dividend

Metric COAG SEPN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric COAG SEPN Biotechnology median
Market cap 2.13b 2.21b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack